



## Appendix 36 - PEDIATRIC ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL)

Approved settings/ treatment line	Protocols	Evidence level
Ph -ve ALL	COG AALL 0331 (Standard risk)	Category 2A
	COG AALL 0232 (High risk)	Category 2A
	DFCI ALL 05-001	Category 2A
	Total therapy XV Regimen	Category 2A
Ph-like ALL	COG AALL 1131 Regimen + Dasatinib	Category 2A
	COG AALL 1521 Regimen + Ruxolitinib	Category 2A
	DFCI-ALL 16-001 Regimen + Dasatinib	Category 2A
	Total therapy XVII Regimen + Dasatinib or Ruxolitinib	Category 2A
Ph +ve ALL	EsPh-ALL Regimen	Category 2A
	COG AALL 0031 Regimen + Imatinib	Category 2A
	COG AALL 0622 Regimen + Dasatinib	Category 2A
	Total therapy XVII Regimen	Category 2A
T-ALL	COG AALL 1231 Regimen	Category 2A
	COG AALL 0434 Regimen	Category 2A
	DFCI-ALL 16-001 Regimen	Category 2A
	SJCRH Regimen	Category 2A
Infant ALL	Interfant Regimens	Category 2A
Ph -ve ALL (Relapse)	High-dose Cytarabine + L-asparaginase	Category 2A
	FLAG-IDA Regimen	Category 2A
	Blinatumomab	Category 2A
	COG AALL07P1 Regimen	Category 2A
	ALL-REZ BFM Regimen	Category 2A
	COG AALL01P2 Regimen	Category 2A
	UKALL R3 Backbone Regimen	Category 2A
Ph +ve ALL (Relapse)	High-dose Cytarabine + L-asparaginase + TKIs	Category 2A
	Blinatumomab (TKI Intolerant)	Category 2A
	COG AALL07P1 Regimen + TKIs	Category 2A
	ALL-REZ BFM Regimen + TKIs	Category 2A
	COG AALL01P2 Regimen + TKIs	Category 2A
	UKALL R3 Backbone Regimen + TKIs	Category 2A
	Inotuzumab ozogamycin (TKI Intolerant)	Category 2A
T-ALL Relapse	Bortezomib, Vincristine, Doxorubicin, Pegaspargase, Corticosteroids.	Category 2A
	BFM Intensification Block1	Category 2A
	UKALL R3 Block1	Category 2A